Skip to main content
See who owns your news
Get Started
SubscribeLogin
Published • loading... • Updated

TRex Bio Prices $117M IPO to Support Immune Drug Work

The South San Francisco biotech sold 8.3 million shares at $14 each to fund trials of drugs that activate regulatory T cells.

Summary by biopharmadive.com
Eli Lilly is the largest equity holder in TRex, which is developing drugs that treat immunological conditions by activating “Treg” cells.

8 Articles

QuartzQuartz
Center

TRex Bio IPO raises $116.7 million, prices at bottom of range

The clinical-stage biotech sold about 8.3 million shares at $14 each, the low end of its $14-to-$16 marketed range

·New York, United States
Read Full Article
Seeking AlphaSeeking Alpha
Lean Right

Eli Lilly-backed TRexBio prices $117M US IPO at $14 per share (LLY:NYSE)

TRex Bio (TRXB) prices its IPO at $14, raising ~$116.7M ahead of its Nasdaq debut Oct. 9.

·Ra'anana, Israel
Read Full Article
biopharmadive.combiopharmadive.com
Center

TRex Bio prices $117M IPO to support immune drug work

Eli Lilly is the largest equity holder in TRex, which is developing drugs that treat immunological conditions by activating “Treg” cells.

Read Full Article
pharmexec.compharmexec.com

Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing

TRexBio and Retension Pharmaceuticals priced IPOs, raising a combined $161.7 million to advance their immunology and hypertension pipelines ahead of their Nasdaq debuts.

Read Full Article
teleborsa.itteleborsa.it

TRex Bio, Supported by Eli Lilly, Collects over 110 Million Dollars with IPO in the USA

(Teleborsa) - TRex Bio, an early-stage biotechnology company focused on autoimmune and inflammatory diseases, raised US$116.7 million in an initial public offering (IPO) in the states...

Read Full Article
endpoints.newsendpoints.news

TRexBio prices $117M IPO for Tregs as Retension lands $45M Nasdaq debut for hypertension

The appetite for biotech IPOs remains strong, especially when Eli Lilly and Nobel Prize-winning science are involved. TRexBio priced its initial stock sale Thursday, raising $116.7 million in ...

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 67% of the sources are Center
67% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

BizToc broke the news on Friday, October 9, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Initial Public Offering (IPO) icon

Initial Public Offering (IPO)

Eli Lilly icon

Eli Lilly

Nobel Prize icon

Nobel Prize

United States icon

United States

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal